Vladimir Putin, Volodymyr Zelenskyy and White House
Digest more
Former Secretary of State Mike Pompeo analyzes what's next in peace negotiations in Ukraine and gives the White House advice on negative coverage of President Donald Trump's meeting with Ukrainian President Volodymyr Zelenskyy on 'America Reports.
1hon MSN
Thank you, Mr. President. Zelenskyy deploys gratitude diplomacy for second visit to Oval Office
Ukrainian President Volodymyr Zelenskyy gushed with gratitude toward President Donald Trump during an Oval Office meeting.
President Trump and NATO's top official have made clear the fate of Ukraine-Russia peace talks rest with Zelenskyy and Putin.
Zelenskyy's sartorial choice seemed carefully designed to insulate him from another unceremonious exit from the Oval Office.
RUSSIA-UKRAINE BILATERAL: President Donald Trump announced yesterday that Russian President Vladimir Putin and Ukrainian President Volodymyr Zelenskyy would hold a bilateral meeting in the coming days. That would be followed by a trilateral meeting with Trump and those two leaders. Trump held a summit with Putin in Alaska on Friday.
After meeting with Russian President Vladimir Putin in Alaska last week, President Donald Trump touted that he had a "very good meeting" with Ukrainian President Volodymyr Zelenskyy and other European leaders at the White House on Monday. Trump ...
Europe has long feared that Trump might give away the farm, striking a deal that stops the war but rewards Putin’s aggression without guaranteeing Ukraine’s safety. But our colleagues report that Zelenskyy may come to today’s meetings willing to make a serious concession: One Ukrainian source says he’d likely OK freezing the war where the battle lines currently stand,
6hon MSN
Trump wants a Zelenskyy-Putin meeting and Hurricane Erin threatens North Carolina: Morning Rundown
Trump meets with Ukraine’s Zelenskyy and other European leaders at the White House. Hurricane Erin forecast to bring life-threatening surf and rip currents to East Coast. And promising medication for children with an ultra-rare and often fatal disease faces a major FDA setback.